Influence of PXR Haplotype Variants on Paclitaxel and Docetaxel Pharmacokinetics and Pharmacodynamics in Asian Cancer Patients

被引：0
|
作者：
Chowbay, Balram [1 ]
Sandanaraj, Edwin [1 ]
Lal, Suman [1 ]
Wang Zhenping [1 ]
Teck, Lim Wan [2 ]
Siang, Ang Cher [2 ]
Lee, Edmund [3 ]
Huat, Tan Eng [2 ]
机构：
[1] Natl Canc Ctr, Div Med Sci, Clin Pharmacol Lab, Singapore 117548, Singapore
[2] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
[3] Natl Univ Singapore, Dept Pharmacol, Singapore, Singapore
来源：
DRUG METABOLISM REVIEWS | 2009年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
123
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] Influence of PXR haplotype variants on paclitaxel pharmacokinetics and pharmacodynamics in Asian cancer patients
    Chowbay, B.
    Sandanaraj, E.
    Lal, S.
    Wang, Z. P.
    Kulkarni, T.
    Lim, W. T.
    Peter, C. S. Ang
    Tan, E. H.
    EJC SUPPLEMENTS, 2008, 6 (12): : 63 - 63
  • [2] The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients
    Miyata, M
    Yasuda, K
    Burioka, N
    Takane, H
    Suyama, H
    Shigeoka, Y
    Endo, M
    Kurai, J
    Morita, M
    Igishi, T
    Shimizu, E
    CANCER JOURNAL, 2006, 12 (01): : 69 - 72
  • [3] PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients
    S Y Hor
    S C Lee
    C I Wong
    Y W Lim
    R C Lim
    L Z Wang
    L Fan
    J Y Guo
    H S Lee
    B C Goh
    T Tan
    The Pharmacogenomics Journal, 2008, 8 : 139 - 146
  • [4] PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients
    Hor, S. Y.
    Lee, S. C.
    Wong, C. I.
    Lim, Y. W.
    Lim, R. C.
    Wang, L. Z.
    Fan, L.
    Guo, J. Y.
    Lee, H. S.
    Goh, B. C.
    Tan, T.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (02): : 139 - 146
  • [5] Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients
    Minami, H
    Kawada, K
    Sasaki, Y
    Igarashi, T
    Saeki, T
    Tahara, M
    Itoh, K
    Fujii, H
    CANCER SCIENCE, 2006, 97 (03) : 235 - 241
  • [6] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
    Bruno, R
    Hille, D
    Riva, A
    Vivier, N
    Huinnink, WWTB
    van Oosterom, AT
    Kaye, SB
    Verweij, J
    Fossella, FV
    Valero, V
    Rigas, JR
    Seidman, AD
    Chevallier, B
    Fumoleau, P
    Burris, HA
    Ravclin, PM
    Sheiner, LB
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 187 - 196
  • [7] Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir
    Maarten van Eijk
    Dick Pluim
    Thomas P. C. Dorlo
    Serena Marchetti
    Alwin D. R. Huitema
    Jos H. Beijnen
    The Pharmacogenomics Journal, 2021, 21 : 336 - 345
  • [8] Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir
    van Eijk, Maarten
    Pluim, Dick
    Dorlo, Thomas P. C.
    Marchetti, Serena
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    PHARMACOGENOMICS JOURNAL, 2021, 21 (03): : 336 - 345
  • [9] Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
    Danesi, R
    Innocenti, F
    Fogli, S
    Gennari, A
    Baldini, E
    Di Paolo, A
    Salvadori, B
    Bocci, G
    Conte, PF
    Del Tacca, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (05) : 508 - 518
  • [10] Influence of Herceptin (HER) on pharmacokinetics (PK) of taxanes (paclitaxel and docetaxel) or gemcitabine (GEM) in breast cancer patients
    Schueller, JJS
    Czejka, MMC
    Ostermann, EEO
    Muric, LLM
    Heinz, DDH
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S129 - S129
12345